Q1 2026 DaVita Inc Earnings Call

May 5, 2026

Operator: Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita Q1 2026 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer period. If you would like to ask a question during this time, simply press star and then the number 1 on your telephone keypad. If you would like to withdraw your question, press star, then the number 2. Thank you. Mr. Eliason, you may begin your conference.

Operator: Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita Q1 2026 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer period. If you would like to ask a question during this time, simply press star and then the number one on your telephone keypad. If you would like to withdraw your question, press star, then the number two. Thank you. Mr. Eliason, you may begin your conference.

Speaker #1: All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer period. If you would like to ask a question during this time, simply press star and then the number 1 on your telephone keypad.

Speaker #1: If you would like to withdraw your question, press star, then the number 2. Thank you. Mr. Eliason, you may begin your conference.

Speaker #2: Thank you, and welcome to our first quarter conference call. We appreciate your continued interest in our company. I'm Nic Eliason, Group Vice President of Investor Relations, and joining me today are Javier Rodriguez, our CEO, and Joel Ackerman, our CFO.

Nic Eliason: Thank you. Welcome to our Q1 Conference Call. We appreciate your continued interest in our company. I'm Nic Eliason, Group Vice President of Investor Relations. Joining me today are Javier Rodriguez, our CEO, and Joel Ackerman, our CFO. Please note that during this call we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our Q1 earnings press release and our SEC filings, including our most recent annual report on Form 10-K, all subsequent quarterly reports on Form 10-Q, and other subsequent filings that we make with the SEC.

Speaker #2: Please note that during this call we may make forward-looking statements within the meaning of the Federal Securities Laws. All of these statements are subject to known and unknown risks and uncertainties, that could cause the actual results to differ materially from those described in the forward-looking statements.

Speaker #2: For further details, concerning these risks and uncertainties, please refer to our first quarter earnings press release and our SEC filings, including our most recent annual report on Form 10-K, all subsequent quarterly reports on Form 10-Q, and other subsequent filings that we make with the SEC.

Speaker #2: Our forward-looking statements are based on information currently available to us, and we do not intend, and undertake no duty, to update these statements except as may be required by law.

Nic Eliason: Our forward-looking statements are based on information currently available to us. We do not intend and undertake no duty to update these statements except as may be required by law. Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our earnings press release furnished to the SEC and available on our website. I will now turn the call over to Javier Rodriguez.

Speaker #2: Additionally, we'd like to remind you that during this call we will discuss some non-gap financial measures. A reconciliation of these non-gap measures to the most comparable gap financial measures is included in our earnings press release furnished to the SEC and available on our website.

Speaker #2: I will now turn the call over to Javier Rodriguez.

Speaker #3: Thank you, Nick. Good afternoon, everyone, and thank you for joining the call today. DAVITA's foundation is clinical excellence, driven by operating rigor that produces durable results.

Javier Rodriguez: Thank you, Nic. Good afternoon, everyone. Thank you for joining the call today. DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results. We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception. To ensure we sustain and build upon this foundation, we're actively investing in our future capabilities. In a rapidly evolving landscape, we're taking a pragmatic approach to expanding our IT systems and digital infrastructure. These targeted technology investments are designed to empower our clinical teams and serve as a backbone for our next chapter of clinical and operational excellence. Today, I'll walk through our Q1 performance, share how technology is enhancing our operations, provide an update on ACA plans, and finish with our outlook for the remaining of the year. First, I'll start, as we always do, with a clinical highlight.

Speaker #3: We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception. To ensure we sustain and build upon this foundation, we're actively investing in our future capabilities.

Speaker #3: In a rapidly evolving landscape, we're taking a pragmatic approach to expanding our IT systems and digital infrastructure. These targeted technology investments are designed to empower our clinical teams and serve as a backbone for our next chapter of clinical and operational excellence.

Speaker #3: Today, I'll walk through our first quarter performance, share how technology is enhancing our operations, provide an update on ACA plans, and finish with our outlook for the remainder of the year.

Speaker #3: But first, I'll start as we always do with a clinical highlight. This quarter, we're highlighting the continued momentum of integrated kidney care or IKC, our value-based care business.

Javier Rodriguez: This quarter, we're highlighting the continued momentum of Integrated Kidney Care, or IKC, our value-based care business. In the latest results from CMS's Comprehensive Kidney Care Contracting program, or CKCC, we delivered year-over-year improvements across all three key measurements, which are gross savings rates, total quality score, and high-performing status. Clinically, this means our IKC care model, together with our physician partners, is improving the health and wellbeing of our patients. Economically, we generated the highest total aggregate savings of any participant, driven by our 4.5% improvement in gross saving rate since the beginning of the program. This is a clear example of how IKC clinical rigor paired with data-driven insights is delivering better outcomes for our patients and more sustainable model for the future of kidney care.

Speaker #3: In the latest results from CMS's comprehensive kidney care contracting program, or CKCC, we delivered year-over-year improvements across all three key measurements, which are gross savings rates, total quality score, and high-performing status.

Speaker #3: Clinically, this means our IKC care model together with our physician partners is improving the health and well-being of our patients. Economically, we generated the highest total aggregate savings of any participant, driven by our 4.5% improvement in gross saving rate since the beginning of the program.

Speaker #3: This is a clear example of how IKC clinical rigor paired with data-driven insights is delivering better outcomes for our patients and more sustainable model for the future of kidney care.

Speaker #3: Turning to the first quarter, we delivered a strong financial result ahead of our expectations. With our performance from each element of our US dialysis trilogy, treatment volume, revenue per treatment, and cost per treatment, this balance-out performance reflects the strength of our team and our focus on consistent execution.

Javier Rodriguez: Turning to Q1, we delivered a strong financial result ahead of our expectations with our performance from each element of our US dialysis trilogy: treatment volume, revenue per treatment, and cost per treatment. This balanced out performance reflects the strength of our team and our focus on consistent execution. I'll touch on a couple of key metrics that contribute to the quarter and will help shape the remainder of the year. Starting with volume. In Q1, our treatment volume was slightly ahead of forecast. Quarter end census was ahead of plan as a result of better than forecasted mortality, partially offset by lower than forecasted admits. Census also benefited from patient transfers in related to ongoing clinic closures by Fresenius. Although negligible in Q1 volume, we anticipate that these transfers will contribute to positive treatment growth over the remainder of the year.

Speaker #3: I'll touch on a couple of key metrics that contributed to the quarter and will help shape the remainder of the year. Starting with volume, in the first quarter, our treatment volume was slightly ahead of forecast.

Speaker #3: Quarter-end census was ahead of plan as a result of better-than-forecasted mortality, partially offset by lower-than-forecasted admits. Census also benefited from patient transfers in related to ongoing clinic closures by Fresenius.

Speaker #3: Although negligible in the first quarter volume, we anticipate that these transfers will contribute to positive treatment growth over the remainder of the year. As a result, we're raising our volume growth expectations for the full year from flat to a range of 25 to 50 basis point increase.

Javier Rodriguez: As a result, we're raising our volume growth expectations for the full year from flat to a range of 25 to 50 basis point increase. Approximately half of the increase is from better underlying performance and half is related to transfer in from Fresenius. Switching to labor. Q1 was ahead of plan, primarily from better productivity, which we expect to sustain over the balance of the year. Let me turn to our technology strategy and the investments we're making to strengthen our operations and ultimately our clinical outcomes. We're taking a disciplined approach to AI that we've been building towards for years. We're seeing that groundwork translate into real impact. Our strategy has two parts. First, we've modernized our data infrastructure. This means standardizing and integrating high-quality data across the enterprise through systems like our proprietary EMR platform.

Speaker #3: Approximately half of the increase is from better underlying performance and half is related to transfer in from Fresenius. Switching to labor, Q1 was ahead of plan, primarily from better productivity which we expect to sustain over the balance of the year.

Speaker #3: Let me turn to our technology strategy and the investments we're making to strengthen our operations and ultimately our clinical outcomes. We're taking a disciplined approach to AI that we've been building towards for years, and we're seeing that groundwork translate into real impact.

Speaker #3: Our strategy has two parts. First, we've modernized our data infrastructure. This means standardizing and integrating high-quality data across the enterprise through systems like our proprietary EMR platform.

Speaker #3: That works, gives us a differentiated foundation to power AI applications at scale. Second, we're actively deploying AI solutions across clinical, operational, and business use cases with a focus on supporting our caregivers, improving how we operate, and drive measurable impact.

Javier Rodriguez: That work gives us a differentiated foundation to power AI applications at scale. Second, we're actively deploying AI solutions across clinical, operational, and business use cases with a focus on supporting our caregivers, improving how we operate, and drive measurable impact. One example is Schedule Hub, a new tool that dynamically processes changes in each center's patient census, capacity, and teammate availability to recommend optimal patient and staffing schedules in real time. Given the complexity of the center scheduling, we expect this will reduce administrative burden for our facility administrators and enhance teammate experience while supporting patient care. This is one of many examples where our sustained IT investments translate into tangible scale benefits across the enterprise. We're still early in our AI journey, but given the strength of our data foundation and the pace of our deployment, we are well-positioned to outperform both clinically and operationally as technology evolves.

Speaker #3: One example is schedule hub. A new tool that dynamically processes changes in each center's patient census, capacity, and teammate availability to recommend optimal patient and staffing schedules in real time.

Speaker #3: Given the complexity of the center's scheduling, we expect this will reduce administrative burden for our facility administrators and enhance teammate experience. While supporting patient care, this is one of many examples where our sustained IT investments translate into tangible scale benefits across the enterprise.

Speaker #3: We're still early in our AI journey, but given the strength of our data foundation, and the pace of our deployment, we are well positioned to outperform both clinically and operationally as technology evolves.

Speaker #3: Next, on ACA plan enrollment, based on what we know today, ACA open enrollment is trending toward a slightly favorable outcome relative to our prior expectations of an approximately 40 million head one in 2026.

Javier Rodriguez: Next, on ACA plan enrollment. Based on what we know today, ACA open enrollment is trending toward a slightly favorable outcome relative to our prior expectations of an approximately $40 million headwind in 2026. This favorability will be partially offset by more patients selecting lower-level bronze plans, which translates to higher out-of-pocket costs and modest RPT headwind. We will gain greater clarity on the enrollment outcome and mix impact as we get deeper into the year. I will conclude my remarks with our financial outlook for the remainder of the year. With our Q1 results, we're off to a strong start for the year. As a result, we're raising and narrowing our guidance for adjusted operating income to a range of $2.15 billion to $2.25 billion.

Speaker #3: This favorability will be partially offset by more patient selecting lower-level bronze plans which translates to higher out-of-pocket cost and modest RPT headwind. We will gain greater clarity on the enrollment outcome and mixed impact as we get deeper into the year.

Speaker #3: I will conclude my remarks with our financial outlook for the remainder of the year. With our first quarter results, we're off to a strong start for the year. As a result, we're raising and narrowing our guidance for adjusted operating income to a range of $2.15 billion to $2.25 billion.

Speaker #3: Similarly, we're raising our adjusted EPS guidance to a range of 14 dollars and 10 cents to 15 dollars and 20 cents per share. The increased guidance is primarily the result of our higher volume forecast for the year and lower patient care cost.

Javier Rodriguez: Similarly, we're raising our adjusted EPS guidance to a range of $14.10 to $15.20 per share. The increased guidance is primarily the result of our higher volume forecast for the year and lower patient care costs. I will now turn the call over to Joel to discuss our financial performance in more detail.

Javier Rodriguez: Similarly, we're raising our adjusted EPS guidance to a range of $14.10 to 15.20 per share. The increased guidance is primarily the result of our higher volume forecast for the year and lower patient care costs. I will now turn the call over to Joel to discuss our financial performance in more detail.

Speaker #3: I will now turn the call over to Joel to discuss our financial performance in more detail.

Speaker #4: Thank you, Javier. Today, I'll provide details on our first quarter results then give you some more context on the update to 2026 guidance that Javier shared.

Joel Ackerman: Thank you, Javier. Today, I'll provide details on our Q1 results, then give you some more context on the update to 2026 guidance that Javier shared. Q1 adjusted operating income was $482 million. Adjusted earnings per share from continuing operations was $2.87, and free cash flow was $140 million. Adjusted operating income came in about $50 million ahead of our forecast. Approximately half was the result of performance ahead of plan and the other half the result of timing. Starting with detail on the US dialysis segment. Treatments declined about 20 basis points versus the Q1 of 2025, and treatments per normalized day increased 40 basis points versus Q1 of 2025, approximately 20 basis points ahead of our expectations.

Speaker #4: First quarter adjusted operating income was 482 million dollars, adjusted earnings per share from continuing operations was 2 dollars and 87 cents, and free cash flow was 140 million dollars.

Speaker #4: Adjusted operating income came in about 50 million dollars ahead of our forecast. Approximately half was the result of performance ahead of plan, and the other half the result of timing.

Speaker #4: Starting with detail on the US dialysis segment, treatments declined about 20 basis points versus the first quarter of 2025, and treatments per normalized day increased 40 basis points versus Q1 of 2025, approximately 20 basis points ahead of our expectations.

Speaker #4: As Javier mentioned, we are increasing our full-year volume forecast by 25 to 50 basis points. As a reminder, this represents our forecast for treatment growth.

Joel Ackerman: As Javier mentioned, we are increasing our full year volume forecast to 25 to 50 basis points. As a reminder, this represents our forecast for treatment growth. This translates to a 50 to 75 basis points of growth in treatments per normalized day because of the year-over-year treatment per normalized day headwind in 2026 compared to 2025. Revenue per treatment declined approximately $5 sequentially, primarily as a result of the typical Q1 headwind from patient pay responsibility. Year-over-year RPT growth was approximately 4% in the quarter. We still expect full year RPT growth in the range of 1% to 2%. Patient care costs per treatment were about flat to the Q4. This was primarily the result of a seasonal decline from high health benefit costs in the Q4, offset by typical increases in wages and other cost growth.

Speaker #4: This translates to a 50 to 75 basis points of growth in treatments per normalized day because of the year-over-year treatment per normalized day headwind in 2026 compared to 2025.

Speaker #4: Revenue per treatment declined approximately 5 dollars sequentially primarily as a result of the typical first quarter headwind from patient pay responsibility. Year-over-year RPT growth was approximately 4% in the quarter.

Speaker #4: We still expect full-year RPT growth in the range of 1 to 2 percent. Patient care cost per treatment were about flat to the fourth quarter.

Speaker #4: This was primarily the result of a seasonal decline from high health benefit costs in the fourth quarter offset by typical increases in wages and other cost growth.

Speaker #4: Patient care costs were lower than expected, largely as a result of better-than-expected productivity improvements. US dialysis G&A costs declined 16 million dollars from the seasonally high fourth quarter although growth versus the first quarter of 2025 was about 37 million dollars or 13%.

Joel Ackerman: Patient care costs were lower than expected, largely as a result of better than expected productivity improvements. US dialysis G&A costs declined $16 million from the seasonally high Q4. Growth versus the Q1 of 2025 was about $37 million or 13%. This growth is the result of continued investment in technology. Turning to our other segments. In the Q1, international adjusted operating income was $30 million, and IKC had an adjusted operating loss of $19 million, both in line with our expectations.

Speaker #4: This growth is the result of continued investment in technology. Turning to our other segments, in the first quarter, international adjusted operating income was $30 million, and IKC had an adjusted operating loss of $19 million, both in line with our expectations.

Speaker #4: Regarding capital allocation, we repurchased 3 million shares during the first quarter and we repurchased an additional 2 million shares since the end of the quarter which includes the shares bought from Berkshire Hathaway pursuant to our repurchase agreement.

Joel Ackerman: Regarding capital allocation, we repurchased 3 million shares during Q1, and we repurchased an additional 2 million shares since the end of the quarter, which includes the shares bought from Berkshire Hathaway pursuant to our repurchase agreement. At the end of Q1, our leverage ratio was 3.34x consolidated EBITDA, well within our target leverage range of 3x to 3.5x. Below the operating income line, other income was $4 million, a sequential increase primarily as the result of no longer recognizing losses from our investment in Mozarc Medical. Debt expense in Q1 was $145 million.

Speaker #4: At the end of the first quarter, our leverage ratio was 3.34 times consolidated EBITDA well within our target leverage range of 3 to 3 and a half times.

Speaker #4: Below the operating income line, other income was 4 million dollars, a sequential increase primarily as the result of no longer recognizing losses from our investment in Mozart.

Speaker #4: Debt expense in the first quarter was 145 million dollars. As an update to our guidance, we now expect quarterly debt expense for the remainder of the year to be similar to Q1 due to higher share repurchases and higher interest rate expectations, resulting in full-year debt expense about flat to last year.

Joel Ackerman: As an update to our guidance, we now expect quarterly debt expense for the remainder of the year to be similar to Q1 due to higher share repurchases and higher interest rate expectations, resulting in full-year debt expense about flat to last year. For 2026 guidance, as Javier described, we are raising our adjusted operating income guidance range by $40 million at the midpoint. The largest driver of the increase is our expectations for higher treatment volume. The second factor is an expectation for continued labor efficiencies with inpatient care costs. Regarding the phasing of our guidance through the balance of the year, we currently expect adjusted operating income to be about evenly split across each of the 3 remaining quarters, which assumes Q4 weighted IKC operating income.

Speaker #4: For 2026 guidance, as Javier described, we are raising our adjusted operating income guidance range by 40 million dollars at the midpoint. The largest driver of the increase is our expectations for higher treatment volume.

Speaker #4: The second factor is an expectation for continued labor efficiencies within patient care costs. Regarding the phasing of our guidance through the balance of the year, we currently expect adjusted operating income to be about evenly split across each of the three remaining quarters which assumes Q4 weighted IKC operating income.

Speaker #4: Our expectations are that the seasonal pattern we saw in 2025 are not typical and we expect to see phasing more in line with 2024.

Joel Ackerman: Our expectations are that the seasonal pattern we saw in 2025 are not typical, and we expect to see phasing more in line with 2024. Moving to EPS, we are also increasing our adjusted EPS guidance consistent with our updated guidance range for adjusted operating income. That concludes my prepared remarks for today. Operator, please open the call for Q&A.

Speaker #4: Moving to EPS, we are also increasing our adjusted EPS guidance consistent with our updated guidance range for adjusted operating income. That concludes my prepared remarks for today.

Speaker #4: Operator, please open the call for Q&A.

Speaker #1: Thank you, sir. If you would like to ask a question during this time, simply press star and then the number one on your telephone keypad.

Operator: Thank you, sir. If you would like to ask a question during this time, simply press star and then 1 on your telephone keypad. If you would like to withdraw your question, press star, then 2. Our first caller is Kevin Fischbeck with Bank of America. Your line is open, sir.

Operator: Thank you, sir. If you would like to ask a question during this time, simply press star and then one on your telephone keypad. If you would like to withdraw your question, press star, then two. Our first caller is Kevin Fischbeck with Bank of America. Your line is open, sir.

Speaker #1: If you would like to withdraw your question, press star, then the number two. Our first caller is Kevin Fishbeck with Bank of America. Your line is open, sir.

Speaker #3: Great, thanks. Wanted to dig in a little bit to the volume commentary. I guess, is there any way that you can kind of break out whether weather had an impact, how much that was, and then the improved mortality?

Kevin Fischbeck: Great, thanks. Wanted to dig in a little bit to the volume commentary. I guess, is there any way that you can kind of break out whether weather had an impact, how much that was? The improved mortality, is there a way to kind of break that into what was maybe just a light flu season year over year versus underlying trends? Just trying to think about how durable, you know, the better mortality is the rest of the year.

Speaker #3: Is there a way to kind of break that into what was maybe just a light flu season year over year versus underlying trends you're trying to think about how durable the better mortality is the rest of the year?

Speaker #4: Yeah, thanks for the question, Kevin. On weather, weather came in exactly as we expected. As you would imagine, we build weather into our forecast.

Joel Ackerman: Thanks for the question, Kevin. On weather came in exactly as we expected. As you would imagine, we build weather into our forecast. It can range from year-to-year. It was, as I said, in line with forecast. I'd say call it about 10 bips better than last year. In terms of flu overall, again, came in line with our forecast. What we had said at the beginning of the year was we were building in a flu season that looked like 2 years ago. While the pattern was a little different quarter-over-quarter, the impact for us was about what we expected. As we think about flu, we focus on cumulative hospitalizations, which you can find on the CDC website, as the main driver of volume impact for us.

Joel Ackerman: Thanks for the question, Kevin. On weather came in exactly as we expected. As you would imagine, we build weather into our forecast. It can range from year-to-year. It was, as I said, in line with forecast. I'd say call it about 10 bips better than last year. In terms of flu overall, again, came in line with our forecast. What we had said at the beginning of the year was we were building in a flu season that looked like two years ago. While the pattern was a little different quarter-over-quarter, the impact for us was about what we expected. As we think about flu, we focus on cumulative hospitalizations, which you can find on the CDC website, as the main driver of volume impact for us.

Speaker #4: It can range from year to year. It was, as I said, in line with forecast. I'd call it about 10 bips better than last year.

Speaker #4: In terms of flu overall, again, came in line with our forecast. What we had said at the beginning of the year was we were building in a flu season that looked like two years ago.

Speaker #4: And while the pattern was a little different quarter over quarter, the impact for us was about what we expected. As we think about flu, we focus on cumulative hospitalizations—which you can find on the CDC website—as the main driver of volume impact for us.

Speaker #4: And this year is in line with what we saw two years ago in terms of splitting out the mortality coming in a little better than expected.

Joel Ackerman: This year is in line with what we saw 2 years ago. In terms of splitting out the mortality coming in a little better than expected, it was probably not about the flu because flu came in as expected. It was more around the underlying mortality.

Joel Ackerman: This year is in line with what we saw two years ago. In terms of splitting out the mortality coming in a little better than expected, it was probably not about the flu because flu came in as expected. It was more around the underlying mortality.

Speaker #4: It was probably not about the flu because flu came in as expected. It was more around the underlying mortality.

Speaker #3: Okay, great. And then can you skip a little more color on the rate update? Why was the rate so strong in Q1 relative to your guidance for the year?

Kevin Fischbeck: Okay, great. Can you just give a little more color on the rate update? Why was the rate so strong in Q1 relative to your guidance for the year?

Speaker #4: Yeah, so rate RPT was up a little more than 4%. So call it 17 and a half dollars. I would say two-thirds of that was normal stuff in terms of rate increases, and mix shifts.

Joel Ackerman: Yeah. rate RPT was up a little more than 4%. call it 17 and a half dollars. I would say two-thirds of that was normal stuff in terms of rate increases and mix shifts. About call it $6 I would attribute to timing. part of that was negative timing in Q1 of 2025, part of it was positive timing this year. We see timing, we call it out frequently around RPT, for the year, we're sticking with our 1% to 2% guide.

Speaker #4: About call it $6, I would attribute to timing. Part of that was negative timing in Q1 of '25, and part of it was positive timing this year.

Speaker #4: We see timing we call it out frequently around RPT, and for the year, we're sticking with our 1 to 2 percent guide.

Speaker #3: Okay, so nothing unusual there around drugs or binders or anything like that that kind of skewed the number?

Kevin Fischbeck: Okay. Nothing unusual there around like drugs and, or binders or anything like that kind of skew the number.

Speaker #4: No, nothing unusual.

Joel Ackerman: No, nothing unusual.

Speaker #3: Okay. And then maybe just the last question. You talked a little bit more about the ACA impact and how you're thinking about it. It sounded like you were saying it was coming in better, but it sounds like the guidance hasn't changed.

Kevin Fischbeck: Okay. Then, maybe just the last question. Can you talk a bit more about the ACA impact and how you're thinking about it? It sounded like you were saying it was coming in better, but it sounds like the guidance hasn't changed yet for the year. Did I get that right? Then, how were you thinking about the timing? Is it that Q1 came in better, and now you're assuming it's gonna ramp, or did you always assume Q1 was gonna be a little bit lighter relative to the year? Thoughts there.

Speaker #3: Yet for the year? I get that right. And then how were you thinking about the timing? Was it that Q1 came in better, and now you're assuming it's going to ramp, or did you always assume Q1 was going to be a little bit lighter relative to the year?

Speaker #3: Thoughts there?

Speaker #4: Yeah, Kevin, it's a great question. And the reality is that it is very early. So just to repeat, Q1 was pretty flattish to Q4.

Joel Ackerman: Yeah, Kevin, it's a great question. The reality is that it is very early. Just to repeat, Q1 was pretty flattish to Q4. It performed better than we expected. That said, the reality is that we haven't seen the effectuation rates and the affordability play out.

Javier Rodriguez: Yeah, Kevin, it's a great question. The reality is that it is very early. Just to repeat, Q1 was pretty flattish to Q4. It performed better than we expected. That said, the reality is that we haven't seen the effectuation rates and the affordability play out.

Speaker #4: So it performed better than we expected. That said, the reality is that we haven't seen the effectuation rates and the affordability play out. And so it's too early.

Javier Rodriguez: It's too early. We have to see payments, and we have to see enrollment over time. That's why we're thinking it's a little premature to change our numbers. The reality is that the real data point that we wanna see is the mix of our future incidents. That is, of course, too early to tell. We're holding to that 40 number, although right now we would be trending 40 million number. We're trending a little better than that.

Speaker #4: We have to see payments, and we have to see enrollment over time. And that's why we're thinking it's a little premature to change our numbers.

Speaker #4: But the reality is that we will need the real data point that we want to see is the mix of our future incidents. And that is, of course, too early to tell.

Speaker #4: So we're holding to that 40 number, although right now we would retrending 40 million number. We're trending a little better than that.

Speaker #3: All right, great. Thanks.

Joel Ackerman: All right, great. Thanks.

Kevin Fischbeck: All right, great. Thanks.

Speaker #4: Thank you.

Javier Rodriguez: Thank you.

Joel Ackerman: Thank you.

Speaker #1: Thank you. Our next caller is Andrew Mock with Barclays. Your line is open, sir.

Operator: Thank you. Our next caller is Andrew Mok with Barclays. Your line is open, sir.

Speaker #5: Hi, good afternoon. Hoping you could provide more color on what you're doing to position yourself to capture market share and the visibility you have into those share gains at this point to raise guidance, specifically related to the clinic closures.

Andrew Mok: Hi, good afternoon. Hoping you could provide more color on what you're doing to position yourself to capture market share and the visibility you have into those share gains at this point to raise guidance, specifically related to the clinic closures.

Speaker #4: Look, at the end of the day, we of course are in a very competitive market. The centers that are being closed, you can assume, are small centers.

Javier Rodriguez: Look, at the end of the day, we, of course, are in a very competitive market. The centers that are being closed, you can assume are small centers, and you can also assume that Fresenius and anyone that closes a center would work hard to try to keep those patients in their own network and with their same physicians, et cetera. We are, of course, making sure that the market is aware of our chair availability and our physician access and all the things that one would do. Of course, the patients and the physicians will make their choice.

Speaker #4: And you can also assume the Fresenius and anyone that closes a center would work hard to try to keep those patients in their own network and with their same physicians, etc.

Speaker #4: And so we are, of course, making sure that the market is aware of our chair availability and our physician access and all the things that one would do.

Speaker #4: And then, of course, the patients and the physicians will make their choice.

Speaker #5: Great. And then I just wanted to follow up on the mortality comment. I appreciate that flu wasn't necessarily the driver, but any color on the underlying mortality performance would be helpful, considering that's an important metric for building consensus and volumes for the balance of the year.

Andrew Mok: Great. I just wanted to follow up on the mortality comment. I appreciate that flu wasn't necessarily the driver, but any color on the underlying mortality performance would be helpful, considering that's an important metric for building consensus and volumes for the balance of the year. Thanks.

Speaker #5: Thanks.

Speaker #4: Yeah, it is an important metric. You're absolutely right about that, Andrew. I would say the changes are rather small. And we're not ready to call out any significant underlying trend.

Joel Ackerman: Yeah. It is an important metric. You're absolutely right about that, Andrew. I would say the changes are rather small and we're not ready to call out any significant underlying trend. That said, we did up the volume guidance and it's captured in there.

Speaker #4: That said, we did up the volume guidance, and it's captured in there.

Speaker #5: I guess how were you able to isolate that it was mortality versus some of the other dynamics in the market with flu and clinic closures?

Andrew Mok: I guess, how were you able to isolate that it was mortality versus, you know, some of the other dynamics in the market with flu and clinic closures?

Joel Ackerman: Clinic closures are a separate issue because they're about admissions, and we've got a lot of visibility on patients coming in and patients leaving. In terms of mortality, as we've said before, it can be a hard variable to know in real time, but we feel pretty good about what we saw from Q1 now that we're sitting here in May.

Speaker #4: Clinic closures are a separate issue because they're about admissions and we've got a lot of visibility on patients coming in and patients leaving in terms of mortality.

Speaker #4: As we've said before, it can be a hard variable to know in real time, but we feel pretty good about what we saw from Q1 now that we're sitting here in May.

Speaker #5: Andrew, I think let me try and be helpful with this. Because you're asking the right question. And there's several inputs that go into treatments, as you can imagine.

Javier Rodriguez: Andrew, I think, let me try and be helpful with this, because you're asking the right question. There's several inputs that go into treatments. As you can imagine, you've got seasonality, you've got mortality, you've got admissions, you've got mistreatments, you've got transfers. They're all pretty small. What we're trying to do is, instead of getting you into a world of small numbers, give you a range that handicaps all of those variables.

Speaker #5: You've got seasonality. You've got mortality. You've got admissions. You've got mistreatments. You've got transfers. But they're all pretty small. And so what we're trying to do is, instead of getting you into a world of small numbers, give you a range that handicaps all of those variables.

Speaker #5: Great. Thank you.

Andrew Mok: Great. Thank you.

Speaker #4: Thank you.

Javier Rodriguez: Thank you.

Speaker #1: And our next caller is Pito Chikkaring with Deutsche Bank. Your line is open, sir.

Operator: Our next caller is Pito Chickering with Deutsche Bank. Your line is open, sir.

Speaker #5: Hey, guys. Thanks for taking my question. Just to follow up on the treatment commentary, can you just talk about the new starts to dialysis in first quarter?

Pito Chickering: Hey, guys. Thanks for taking my question. Just to follow up on the treatment commentary, can you just talk about the new starts to dialysis in Q1? As you think about Fresenius scaling in, you know, from their closures, is this an immediate ramp in sort of Q1, Q2 and then normalizing the H2? I just wanna make sure that as you're increasing your treatment growth guidance here, that we're also modeling, you know, where you guys go from Q2 and then where you guys finish the year in Q4.

Speaker #5: And as you think about Fresenius scaling in, from their closures, is this an immediate ramp in sort of 1Q, 2Q, and then normalizing back half a year?

Speaker #5: Just want to make sure that as you're increasing your treatment growth guidance here, that we're also modeling where you guys go from 2Q and then where you guys finish the year in fourth quarter.

Speaker #4: Yeah. So on the admit side, I don't think we've got a lot of color to go in. We're talking about basis points of change and then to go to the next level and bifurcate that among all the inputs that Javier mentioned.

Joel Ackerman: Yeah. on the admit side, I don't think we've got a lot of color to go in. You know, we're talking about basis points of change and then to go to the next level and bifurcate that among all the inputs that Javier mentioned, I think gets us to a point of false precision. In terms of timing on the new starts, we saw what I would guess is about half the new starts from Fresenius that we would see by the end of Q1. We would guess the other half will come in Q2. if you're thinking about how to model them, I would say we'll get probably two-thirds of a year worth of those new starts.

Speaker #4: I think it gets us to a point of false precision. In terms of timing on the new starts, we saw what I would guess is about half the new starts from Fresenius that we would see by the end of the first quarter. We would guess the other half will come in Q2.

Speaker #4: So if you're thinking about how to model them, I would say we'll get probably two-thirds of a year worth of those new starts.

Speaker #5: So just when you pull it together with the new starts and the mortality and the Fresenius, kind of where should we be ending the fourth quarter from a treatment organic treatment growth perspective?

Pito Chickering: Just, you know, when we pull it together with the new starts, the, you know, mortality and the Fresenius kind of where should we be ending the, you know, Q4 from a treatment, organic treatment growth perspective?

Speaker #4: Yeah, I think the way we're thinking about it is treatments per normalized day. Which we think takes out the quarter-to-quarter and year-to-year noise associated with the different number of days in a quarter and the different mix of Monday, Wednesday, Friday, Tuesday, Thursday, Saturday.

Joel Ackerman: Yeah. I think, the way we're thinking about it is treatments per normalized day, which we think takes out the quarter-to-quarter and year-to-year noise associated with the different number of days in a quarter and the different mix of Monday, Wednesday, Friday, Tuesday, Thursday, Saturday. What we would expect is the normalized treatment per day count to grow over the course of the year. It's sitting today at about 40 Bips positive, and we would expect that to grow over the course of the year. Just to make sure everyone's following how we're thinking about this, our new guide for treatment volume is +25 to 50 Bips. Because there's a 25-day headwind in the year on normalized treatment days, our guide for the year would be +50 to 75 Bips of normalized treatments per day.

Speaker #4: So what we would expect is the normalized treatment per day count to grow over the course of the year. It's sitting today at about 40 bips positive and we would expect that to grow over the course of the year.

Speaker #4: Just to make sure everyone's following how we're thinking about this, our new guide for treatment volume is plus 25 to 50 bips. Because there's a 25-day headwind in the year on normalized treatment days, our guide for the year would be plus 50 to 75 bips of normalized treatments per day.

Speaker #4: So that's 40 now getting to that average of 50 to 75 for the year ending somewhere higher than that.

Joel Ackerman: That's 40 now getting to that average of 50 to 75 for the year, ending somewhere higher than that.

Speaker #5: Okay, great. And then a follow-up here on the revenue per treatment. If you pull out the $6 you're talking about from a timing perspective, it gets us to 411 and 412.

Pito Chickering: Okay, great. Then a follow-up here on the revenue per treatment. If you pull out the $6 you're talking about from a timing perspective, you know, it gets us to $411 or $412. Typically, two key ramps, you know, $4 or $5 as you burn through the deductibles, then we see continued ramp in the Q3. Then obviously Q4, we get the update with the new Medicare rates. I guess I'm trying to figure out how we're still getting to your 1% to 2% revenue per treatment guidance growth, even pulling out the $6 in the Q4 from the Q1 because of normal seasonality you guys see in revenue?

Speaker #5: Typically, 2Q ramps 4 or 5 dollars. As we point to the deductibles and then we see continue ramp in the third quarter and then obviously fourth quarter we get the update with the new Medicare rates.

Speaker #5: I guess I'm trying to figure out how we're still getting to your 1 and 2 percent revenue per treatment guidance growth even pulling out the $6 in the fourth quarter from the first quarter in terms of normal seasonality you guys see in revenue treatment.

Speaker #4: Yeah, so I think there are two dynamics. One is normal variability. So the quarter was a little higher and you take that out. The second dynamic is around mix and the enhanced premium tax credits.

Joel Ackerman: Yeah. I think there are two dynamics. One is normal variability. The quarter was a little higher, and you take that out. The second dynamic is around mix and the enhanced premium tax credits. What we would expect is commercial mix to decline over the course of the year, and that'll put pressure on RPT, which would help you bridge from a higher number in Q1 to the 1% to 2% for the year.

Speaker #4: What we would expect is commercial mix to decline over the course of the year. And that'll put pressure on RPT, which would help you bridge from a higher number in Q1 to the 1 to 2 percent for the year.

Speaker #5: Okay, but at this point through April, you haven't seen that negative hicks that you're guiding to. You're just sort of just assuming it comes until we get later on the year.

Pito Chickering: Okay. At this point, through April, you haven't seen that negative mix that you're guiding to. You're just sort of just assuming it comes until later on the year.

Joel Ackerman: That's correct.

Speaker #4: That's correct.

Joel Ackerman: That's correct.

Speaker #5: Okay, and then last question. GNA per treatment, you talked about was up 13% due to tech investments. Where does it end the year and kind of should we think about this declining linear throughout the year as those investments are made or just any color around how it should be modeling GNA treatments per a GNA cost per treatment throughout the year as the tech investments begin to decline?

Pito Chickering: Okay. Last question, your G&A per treatment, you know, you talked about was up, you know, 13% due to tech investments. You know, where does it end the year and kind of should we think about this, you know, declining linear throughout the year as those investments are made, or just any color around how we should be modeling G&A cost per treatment throughout the year as the tech investments begin to decline. Thank you.

Speaker #5: Thank you.

Speaker #4: Yeah, appreciate the question on GNA. And I want to reassure you, that we are looking at this incredibly diligently. And if one looks at GNA independently, that line is growing at a faster rate than revenue.

Joel Ackerman: Appreciate the question on G&A. I want to reassure you that we are looking at this incredibly diligently. If one looks at G&A independently, that line is growing at a faster rate than revenue. I think it's worthwhile to let you know our philosophy on it, which is we look at G&A as a piece of the total cost. In other words, we're not trying to optimize G&A, but rather not worry about the geography of the expense as long as the sum of the parts add up to a good number. If you look at the last 5 years CAGR on our total cost, which includes patient care cost, depreciation, amortization, and G&A, that CAGR is 2.6%.

Joel Ackerman: Appreciate the question on G&A. I want to reassure you that we are looking at this incredibly diligently. If one looks at G&A independently, that line is growing at a faster rate than revenue. I think it's worthwhile to let you know our philosophy on it, which is we look at G&A as a piece of the total cost. In other words, we're not trying to optimize G&A, but rather not worry about the geography of the expense as long as the sum of the parts add up to a good number. If you look at the last five years CAGR on our total cost, which includes patient care cost, depreciation, amortization, and G&A, that CAGR is 2.6%.

Speaker #4: And so I think it's worthwhile to let you know our philosophy on it, which is we look at GNA as a piece of the total cost.

Speaker #4: In other words, we're not trying to optimize GNA but rather not worry about the geography of the expense as long as it's some of the parts add up to a good number.

Speaker #4: So if you look at the last five years, Keger on our total cost, which includes patient care costs, depreciation, amortization, and GNA, that Keger is 2.6%.

Speaker #4: And so we spend a lot of time trying to make sure that we optimize the cost and we worry less about the geography on the P&L.

Joel Ackerman: We spend a lot of time trying to make sure that we optimize the cost, and we worry less about the geography on the P&L. I think that our guide will stand on our cost, which is that 1.25% to 2.25% we gave at the beginning of the year.

Speaker #4: So I think that our guide will stand on our cost, which is that 1.25 to 2.25 percent we gave at the beginning of the year.

Speaker #5: All right, great. Thanks so much and great quarter, guys. Appreciate it.

Pito Chickering: All right. Great. Thanks so much, and great quarter, guys. Appreciate it.

Speaker #4: Thank you.

Joel Ackerman: Thank you.

Speaker #6: Thank you. And as a reminder, if you would like to ask a question, you may press star one. Our next caller is Justin Lakewood, Wolf Research.

Operator: Thank you. As a reminder, if you would like to ask a question, you may press star one. Our next caller is Justin Lake with Wolfe Research. Your line is open, sir.

Speaker #6: Your line is open, sir.

Speaker #7: Hi, this is Dylan on for Justin. Just a couple of quick questions. What did commercial mix do in the quarter and then also curious on the Medicare Advantage side, can you speak a little bit about what the growth in share was as well?

[Analyst] (Wolfe Research): Hi, this is Dylan on for Justin. Just a couple quick questions. What did commercial mix do in the quarter? Also curious on the Medicare Advantage side, can you speak a little bit about what the growth in share was as well? Thanks.

Dylan Nassano: Hi, this is Dylan on for Justin. Just a couple quick questions. What did commercial mix do in the quarter? Also curious on the Medicare Advantage side, can you speak a little bit about what the growth in share was as well? Thanks.

Speaker #7: Thanks.

Speaker #4: Yeah, thanks, Dylan, for the question. The answer is pretty much the same on both. They were pretty flat relative to last quarter.

Joel Ackerman: Yeah. Thanks, Dylan, for the question. The answer is pretty much the same on both. They were pretty flat relative to last Q.

Joel Ackerman: Yeah. Thanks, Dylan, for the question. The answer is pretty much the same on both. They were pretty flat relative to last quarter.

Speaker #6: Okay, would you like to go to the next question?

Operator: Okay. Would you like to go to the next question?

Speaker #4: Please, Michelle.

Joel Ackerman: Please, Michelle.

Javier Rodriguez: Please, Michelle.

Speaker #6: AJ Rice from UBS. Your line is open, sir.

Operator: A.J. Rice from UBS, your line is open, sir.

A.J. Rice: Hi, everybody. Maybe just ask on a couple of items that are mentioned in the press release, whether there's anything significant to call out. You talk about a decrease year to year in health benefit expense, pharmaceutical cost, and then on the G&A line, professional fees. Was this sort of as expected, or was there anything unusually positive that happened there? Just asking.

Speaker #8: Hi, everybody. Maybe just ask on a couple of items that are mentioned in the press release, whether there's anything significant to call out. You talk about a decrease year to year in health benefit expense, pharmacy pharmaceutical cost, and then on the G&A line, professional fees.

Speaker #8: Was there sort of as expected or was there anything unusually positive that happened there? Just asking.

Speaker #4: Yeah, AJ, it was as expected. We'll often see the declines sequentially from Q4 to Q1, especially in health benefits. So nothing unusual there.

Joel Ackerman: Yeah. A.J., it was as expected. We'll often see the decline sequentially from Q4 to Q1, especially in health benefits. Nothing unusual there.

Speaker #8: Okay. And then I appreciate the comments about the technology investments and some of the use cases you're looking at. Is there any way realizing even if you get savings, you may choose to reinvest it in other ways?

A.J. Rice: Okay. I appreciate the comments about the technology investments and some of the use cases you are looking at. Is there any way, realizing even if you get savings, you may choose to reinvest it in other ways, but is there any way to sort of size some of the opportunities you see? Are those being reflected now in operating results, or what is your thought about how long it may take for the sum of this to impact operating performance?

Speaker #8: But is there any way to sort of size some of the opportunities you see and are those being reflected now in operating results or what is your thought about how long it may take for some of this to impact operating performance?

Speaker #4: Yeah, I appreciate the question. I think the way we look at it is the long-term view. That we again are trying to ensure that we are putting our clinicians in the best position and that we're making the trade-off on efficiency for the long term to make sure that we sustain our three to seven percent OI growth over time.

Joel Ackerman: Yeah, appreciate the question. I think the way we look at it is the long-term view.

Javier Rodriguez: That we again are trying to ensure that we are putting our clinicians in the best position and that we're making the trade-off on efficiency for the long term to make sure that we sustain our 3% to 7% OI growth over time. As you know, right now, technology is moving at a very quick pace, and some of these will be a lot of user experience, i.e., we're just enhancing the experience, and some of these will be helpful toward the bottom line. It's a little early, and I don't think we wanna get into the timing of it, but rather the sustainability and the outperformance of it.

Joel Ackerman: That we again are trying to ensure that we are putting our clinicians in the best position and that we're making the trade-off on efficiency for the long term to make sure that we sustain our 3% to 7% OI growth over time. As you know, right now, technology is moving at a very quick pace, and some of these will be a lot of user experience, i.e., we're just enhancing the experience, and some of these will be helpful toward the bottom line. It's a little early, and I don't think we wanna get into the timing of it, but rather the sustainability and the outperformance of it.

Speaker #4: And so as you know, right now, technology is moving at a very quick pace. And some of these will be a lot of user experience, i.e., we're just enhancing the experience.

Speaker #4: And some of these will be helpful toward the bottom line. And it's a little early and I don't think we want to get into the timing of it, but rather the sustainability and the outperformance of it.

Speaker #8: Okay, thanks a lot.

A.J. Rice: Okay. Thanks a lot.

Speaker #4: Thank you.

Javier Rodriguez: Thank you.

Speaker #6: And our next caller is Ryan Langston with TD Cowan. Your line is open, sir.

Operator: Our next caller is Ryan Langston with TD Cowen. Your line is open, sir.

Speaker #9: Thanks. Good afternoon. Nice to see the operating income guide up, EPS guide up as well. I noticed a free cash flow guide did not change.

Ryan Langston: Thanks. Good afternoon. Nice to see the operating income guide up, EPS guide up as well. I noticed the free cash flow guide did not change. I think this was a similar dynamic last year. Just wanted to confirm that's normal course and nothing specific to read into.

Speaker #9: I think this was a similar dynamic last year. Just wanted to confirm that's normal course and nothing specific to read into.

Speaker #4: Yeah, Ryan, you're thinking about it the right way. There's just more variability and a wider range with free cash flow, so we didn't move the number despite the increase in OI.

Joel Ackerman: Yeah. Ryan, you're thinking about it the right way. There's just more variability and a wider range with free cash flow. We didn't move the number despite the increase in OI.

Javier Rodriguez: Yeah. Ryan, you're thinking about it the right way. There's just more variability and a wider range with free cash flow. We didn't move the number despite the increase in OI.

Speaker #9: Okay. And then this administration is really focused on fraud, waste, abuse. It seems to me dialysis might be a little better insulated versus other types of providers.

Ryan Langston: Okay. This administration is really focused on fraud, waste, and abuse. It seems to me dialysis might be a little better insulated versus other types of providers. Just any general thoughts on, you know, this administration's focus on that FWA and what this could mean potentially for DaVita or maybe not mean for DaVita or even just more broadly for dialysis in general?

Speaker #9: Just any general thoughts on this administration's focus on that FWA and what this could mean potentially for DaVita or maybe not mean for DaVita or even just more broadly for dialysis in general?

Javier Rodriguez: Yeah. Thanks for the question. It's tough for us to comment on the broader environment, but what I can say is we take compliance incredibly seriously. Number 2, what we do have a little help in is that dialysis is not a controversial diagnosis. There's not like, "Oh, should I go get this treatment or not?" controversy. That makes it easier. The fact that it is a bundle in a single DRG, in essence, simplifies some of the compliance issues. Again, we are internally focused on making sure we do right by the government.

Speaker #4: Yeah, thanks for the question. It's tough for us to comment on the broader environment, but what I can say is we take compliance incredibly seriously.

Javier Rodriguez: Yeah. Thanks for the question. It's tough for us to comment on the broader environment, but what I can say is we take compliance incredibly seriously. Number two, what we do have a little help in is that dialysis is not a controversial diagnosis. There's not like, "Oh, should I go get this treatment or not?" controversy. That makes it easier. The fact that it is a bundle in a single DRG, in essence, simplifies some of the compliance issues. Again, we are internally focused on making sure we do right by the government.

Speaker #4: And number two, what we do have a little help in is that dialysis is not a controversial diagnosis. So there's not like, "Oh, should I go get this treatment or not?" controversy.

Speaker #4: So that makes it easier. And then the fact that it is a bundle in a single DRG, in essence, simplifies some of the compliance issues but again, we are internally focused on making sure we do right by the government.

Speaker #9: Great. Thank you.

Ryan Langston: Great. Thank you.

Speaker #6: And thank you. At this time, I'm showing no further questions. Speakers, I'll turn the call back over to you for closing comments.

Operator: Thank you. At this time, I'm showing no further questions. Speakers, I'll turn the call back over to you for closing comments.

Speaker #4: Okay, thank you, Michelle, and thank you all for joining the call today. I would wrap up with three takeaways. First, our most recent clinical initiatives are beginning to gain traction, and we're seeing early signs of the benefits for our patients.

Javier Rodriguez: Okay. Thank you, Michelle, and thank you all for joining the call today. I would wrap up with three takeaways. First, our most recent clinical initiatives are beginning to gain traction, and we're seeing early signs of the benefits for our patients. Second, our business is performing well. As we continue to achieve our clinical goals, this drives our strong financial results. Finally, we maintain a long-term view on our business and will continue to invest in our future. Thank you all for joining this quarter. Be well, and we look forward to seeing you next time. Happy Cinco de Mayo, everyone.

Speaker #4: Second, our business is performing well as we continue to achieve our clinical goals. This drives our strong financial results. And finally, we maintain a long-term view on our business and will continue to invest in our future.

Speaker #4: Thank you all for joining this quarter. Be well and we look forward to seeing you next time. Happy Cinco de Mayo, everyone.

Operator: Thank you. This concludes today's conference call. You may go ahead and disconnect at this time.